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 ABSTRACT 
 Vaccination can play a useful role in mastitis control 
programs, although there is a relative dearth of large, 
well-controlled field efficacy studies. This paper pres-
ents the findings on the use of a commercially available 
vaccine (Startvac, Hipra UK Ltd., Nottingham, UK) on 
commercial units under UK field conditions. In total, 
3,130 cows were recruited from 7 farms and were ran-
domly allocated, within farm, to 1 of 3 groups. The first 
group received the vaccine following the label regimen, 
the second group was vaccinated every 90 d following an 
initial vaccination course, and the third group was left 
unvaccinated to act as controls. Vaccine efficacy was 
assessed in the first 120 d of lactation. Data were avail-
able for analysis from 1,696 lactations in 1,549 cows. 
In total, 779 cases of clinical mastitis occurred in the 3 
study groups, and we detected no significant difference 
in the incidence or prevalence of clinical or subclinical 
mastitis between any of the 3 groups. Mastitis vaccina-
tion following the label regimen was associated with a 
significant reduction in the severity of clinical cases. 
Cows in this group were at significantly decreased odds 
of developing clinical mastitis presenting with more 
than just milk changes [odds ratio: 0.58; 95% confidence 
interval (CI): 0.35–0.98]. Similarly, each additional vac-
cination resulted in a cow being at decreased odds of 
developing clinical mastitis presenting with more than 
just milk changes (odds ratio: 0.87; 95% CI: 0.77–0.98). 
Although no cows were culled because of severe mas-
titis in either of the vaccinated groups, we detected 
no significant difference in the mastitis-related culling 
rate between groups. Analysis of milk production data 
demonstrated that, on average, cows on the label regi-
men produced a higher volume of milk (231 L; 95% CI: 
104.1–357.4) and more milk solids (12.36 kg; 95% CI: 
3.12–21.60) than unvaccinated cows in the first 120 d of 
lactation. Conservative analysis suggested that a return 
on investment of 2.57:1 could be expected under UK 
conditions based on increased milk yield alone. 
 Key words:   vaccination ,  mastitis ,  milk production , 
 coliform ,  Escherichia coli 
 INTRODUCTION 
 Clinical and subclinical mastitis remain a major cause 
of financial loss to the dairy industry and a significant 
challenge to the dairy producer, with a large number 
of herds still experiencing unacceptable levels of disease 
(Bradley et al., 2007b). Several treatments and control 
measures are available to the practitioner but these are 
often apparently insufficient to control the disease on 
farm (Green et al., 2007). 
 Effective mastitis vaccination has long been the “holy 
grail” of mastitis control. However, despite develop-
ment of several vaccines in the 1980s, based on the 
J5 Escherichia coli mutant, such vaccines to date, al-
though demonstrating an ability to reduce the severity 
of clinical signs and duration of infection, have failed to 
demonstrate a reduction in the rate of IMI (Hogan et 
al., 1992; Wilson et al., 2007a). Investigation of the use 
of J5 coliform vaccines has also demonstrated a positive 
effect on production in that vaccinated cows have been 
shown to recover milk yield after a clinical case more 
quickly than unvaccinated cows (Wilson et al., 2007b, 
2008, 2009). 
 Although mastitis vaccines have been available in 
many jurisdictions, this has not been the case in the 
European Union until relatively recently. However, 
a polyvalent mastitis vaccine directed against both 
enterobacterial and staphylococcal species has been 
approved for use in the European Union (Startvac; 
Hipra UK Ltd., Nottingham, UK). Registration stud-
ies demonstrated a reduction in IMI with coliform 
and Staphylococcus spp. and a decrease in severity of 
clinical signs of disease when using the product (http://
www.ema.europa.eu/docs/en_GB/document_library/
EPAR_-_Scientific_Discussion/veterinary/000130/
WC500068576.pdf). However, these registration studies 
were based primarily in southern Europe and were con-
ducted under very different climatic and management 
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conditions to those seen in northern Europe and the 
United Kingdom.
A significant constraint to the use of mastitis vac-
cines has been the relatively onerous vaccination regi-
mens (Wilson and González, 2003) that are necessary 
to achieve the desired level of efficacy. These often 
necessitate vaccination both before and after calving 
(González et al., 1989). This has led to the develop-
ment of more practical, farmer-friendly approaches to 
vaccination when J5 core antigen vaccines have been 
deployed in the field, such as a rolling schedule of vac-
cination of all cows in the herd on a quarterly basis. 
Other attempts at improving efficacy have also been 
made by increasing the number of vaccinations (Erskine 
et al., 2007) and by vaccinating earlier in the lactation 
cycle (Gurjar et al., 2013), in part to reduce the effect 
of IMI acquired during the dry period (Bradley and 
Green, 2000).
The aim of the study outlined here was to investigate 
the efficacy of a multivalent mastitis vaccine (Startvac; 
Hipra UK Ltd.) in the control of bovine mastitis under 
UK field conditions using both the label regimen and a 
schedule of quarterly vaccination.
MATERIALS AND METHODS
Herd Selection
Seven commercial dairy herds, in the southwestern 
United Kingdom, were selected to participate in the 
study based on location, likelihood of compliance with 
the study protocol, suitable herd records, a suitably 
maintained milking machine, and enrollment in regular 
DHI testing. No strict criteria were applied pertaining 
to bulk milk SCC or clinical mastitis incidence. Each 
herd was visited by a veterinarian to provide suitable 
training to ensure study compliance.
Cow Selection
All cows and heifers approaching their first calving 
were eligible for recruitment to the study, contingent 
on being in good health, having 4 functional quarters, 
teats free of significant teat lesions, and an estimated 
calving date to allow vaccination at predicted times 
before calving.
Vaccine Selection
The vaccine selected for use in this study (Startvac; 
Hipra UK Ltd.) was a polyvalent product containing 
inactivated Escherichia coli J5 and inactivated Staphy-
lococcus aureus (CP8) strain SP 140, expressing slime-
associated antigenic complex (SAAC), utilizing a liquid 
paraffin adjuvant and containing benzyl alcohol as an 
excipient.
Study Protocol
Enrollment. Farms were initially visited and all 
lactating and nonlactating adult cows present on the 
farm were recruited to the study. Herd personnel were 
trained to maximize compliance with the study proto-
col. Training encompassed the identification, scoring, 
and aseptic sampling of clinical mastitis and the use 
of the California Mastitis Test. Thereafter, each site 
was visited weekly to allow recruitment of heifers and 
purchased cows joining the herd as well as the colla-
tion of farm records, sample collection, reinforcement 
of training, and the administration of vaccinations as 
outlined below.
Treatment Allocation and Administration. At 
the initial visit to each site, all eligible cows were ran-
domly allocated to 1 of the 3 study groups; namely, 
unvaccinated, label, and rolling regimen groups. 
Thereafter, cows joining the herd were also randomly 
allocated to 1 of the 3 study groups. Heifers were re-
cruited if service dates had been accurately recorded. 
Once enrolled, cows remained in the same treatment 
group for subsequent lactations. All vaccinations were 
administered by study personnel.
Cows in the unvaccinated group acted as negative 
controls and did not receive any vaccinations. Cows 
recruited to the label and rolling groups were vacci-
nated (by deep intramuscular injection) according to 
the schedule outlined below. The study was conducted 
under field conditions and, therefore, vaccinations were 
carried out weekly, with all vaccinations due in the next 
7 d being undertaken at each visit (i.e., cows due to 
be vaccinated 45 d before calving may have been vac-
cinated between 52 and 45 d before calving).
Rolling Vaccination Regimen. Cows recruited to 
the rolling group were vaccinated on the day of recruit-
ment (d 0), 28 d later (d 28), 62 d thereafter (d 90), 
and then every 90 d until the end of the study. New 
cows entering the herd were vaccinated at the earliest 
opportunity and followed the same regimen, although 
they received their vaccinations at a different time from 
the majority of cows that entered this regimen.
Label Vaccination Regimen. Cows recruited to 
the label group were not vaccinated on enrollment but 
were monitored and subsequently vaccinated according 
to the licensed regimen at 45 d before the estimated 
date of calving (based on herd records), 35 d later (10 d 
before the estimated date of calving, although this could 
actually be postcalving if cows calved early), and 52 d 
postcalving. Label regimen cows were not vaccinated 
again until 45 d before their next estimated calving date.
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Masking and Bias-Reducing Methods. It was 
not possible to completely blind study or farm per-
sonnel to product administration because no placebo 
was administered. However, the potential for bias was 
reduced by the use of randomization tables in the allo-
cation of cows to treatment group and because no form 
of identification was used that allowed visual identifica-
tion of cows based on their treatment group. Moreover, 
although it was possible for bias to be introduced in 
the subjective identification of clinical mastitis, other 
outcomes used in the study such as yield and SCC 
could not be influenced by study personnel. Labora-
tory personnel undertaking somatic cell counting and 
clinical mastitis bacteriology were completely blind to 
product administration.
Clinical Mastitis and Production Monitoring. 
Farm personnel monitored cows for the presence of clin-
ical mastitis throughout the study period and collected 
a pretreatment aseptic quarter milk sample when cases 
occurred. These samples were frozen on farm and stored 
until the next routine visit. All personnel were trained 
in detection, grading, and aseptic sampling of clini-
cal mastitis following standard operating procedures. 
Clinical mastitis cases were scored for clinical severity 
(grade 1 = milk changes only; grade 2 = milk or udder 
changes or both; grade 3 = signs of systemic disease 
(e.g., loss of appetite, change in demeanor, elevated 
rectal temperature, >39.2°C) with or without milk or 
udder changes; grade 4 = signs of severe depression and 
toxemia or toxic shock).
Individual cow production was monitored through 
an International Committee for Animal Recording 
(ICAR)-accredited milk recording scheme run by 
QMMS Ltd. (Somerset, UK).
Laboratory Procedures
All milk samples collected were maintained at 
or below 8°C during transport to the laboratory for 
analysis. Microbiological investigation and SCC were 
carried out using the standard milk sample examina-
tion techniques, which exceeded the standard recom-
mended by the International Dairy Federation (Bul-
letin No 132), International Standard 13366–1:1997 (E) 
and 13366–2:1997 (G; International Dairy Federation, 
1981). A more complete description of these techniques 
is outlined below.
Bacteriology. Ten microliters of secretion was in-
oculated onto sheep blood agar and Edward’s agar, and 
100 μL of secretion was inoculated onto MacConkey 
agar to enhance the detection of Enterobacteriaceae. 
Plates were incubated at 37°C and read at 24, 48, and 
72 h. Organisms were identified and quantified using 
standard laboratory techniques (Quinn et al., 1994; Na-
tional Mastitis Council, 1999) and matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry 
(MALDI-TOF MS; MALDI Biotyper, Bruker Dal-
tonics, Billerica, MA).
The primary method used to identify organisms was 
MALDI-TOF MS. Individual colonies selected for the 
purposes of identification were applied to a steel plate 
(Bruker Daltonics) and allowed to dry at room tem-
perature before overlay with 1 μL of MALDI Matrix 
[a saturated solution of α-cyano-4-hydroxycinnamic 
acid (Bruker Daltonics) in 50% acetonitrile and 2.5% 
trifluoroacetic acid]. Spectra were generated using the 
manufacturer’s suggested settings and captured and 
analyzed using the flexControl and MALDI Biotyper 
3.0 software (Bruker Daltonics). Ions were generated 
with a 337-nm nitrogen laser and captured in the 
positive linear mode in a mass range of 2 to 20 kDa. 
Spectra were compared with a database containing in 
excess of 3,500 spectra from over 2,000 bacterial spe-
cies. Each plate also carried a standard (Bacterial Test 
Standard, Bruker Daltonics) to calibrate the instru-
ment and validate each run. Organisms were identi-
fied using criteria outlined by the manufacturer; this 
method uses an integrated pattern-matching algorithm 
to match spectral peaks against known bacterial species 
before assigning a log score against a maximum value 
of 3.0. For the purposes of this study, identifications 
were only accepted where a score >2.0 was achieved 
and a “probable” species-level identification applied 
that was also consistent with colony and organism mor-
phological characteristics. In the very small number of 
cases in which a species-level identification could not 
be achieved, conventional biochemical techniques were 
used such as API (bioMérieux, Basingstoke, UK).
Somatic Cell Counting. Samples were collected 
into vials containing an 18-mg tablet containing 8 mg 
of bronopol and 0.30 mg of natamycin (Broad Spec-
trum Microtabs II, Advanced Instruments Inc., Nor-
wood, MA). The SCC was determined using the Fos-
somatic method (Delta CombiScope, model FTIR 400, 
Drachten, the Netherlands), according to the FIL-IDF 
148 A: 95 norm (International Dairy Federation, 1995).
Assessment of Efficacy
For the purposes of the analysis outlined in this paper, 
efficacy of the different vaccination regimens was com-
pared with no vaccination in the first 120 d of lactation. 
This period was selected because it corresponded to 
the period of expected efficacy when following the label 
vaccination regimen. To conduct the analysis, a suit-
able population of cows had to be selected from among 
those recruited to the study to ensure sufficient time 
had elapsed following vaccination for a “protective” im-
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mune response to have been raised and to ensure groups 
could be compared in a contemporaneous manner. This 
was achieved using the following process. Label cows 
were included if they had received at least 2 vaccina-
tions before calving. Rolling cows were included in the 
analysis if they had received at least 2 vaccinations 
before calving. In both vaccinated groups, the time be-
fore calving of the second vaccination was controlled for 
as a potentially confounding factor. Unvaccinated cows 
were only recruited if sufficient time had elapsed since 
enrollment for them to have received 2 vaccinations 
had they been in either of the other treatment groups, 
thereby ensuring all 3 groups were temporally matched.
Clinical Mastitis. Both overall and pathogen-spe-
cific clinical mastitis rates were investigated in the first 
120 d of lactation. The effect of vaccination on clinical 
mastitis severity was assessed using all cases of clinical 
mastitis occurring in the first 120 d lactation.
SCC. The effect of vaccination on SCC was assessed 
in several ways, primarily by investigating the effect on 
SCC at each of the first 4 individual recordings in lacta-
tion (as long as they occurred with 120 d of calving). 
First, second, third, and fourth test-days were defined 
by their timing during lactation, occurring at 5 to 30, 
31 to 60, 61 to 90, and 91 to 120 d in milk, respectively. 
In addition, using SCC as a proxy for infection status 
and a threshold of 200,000 cells/mL, the apparent prev-
alence of infection at the first recording (within 30 d 
of calving) was assessed. In addition, the apparent dry 
period cure and dry period new infection rates were cal-
culated, based on movements around the 200,000 cells/
mL threshold, using the last SCC before dry off and the 
first SCC postcalving (Green et al., 2008). Finally, the 
apparent rate of new infection during lactation in the 
first 120 d of lactation was assessed using movements 
around the same SCC threshold between successive 
dairy herd improvement tests (Bradley et al., 2007a).
Milk Yields. The effect of vaccination on milk yield 
and milk solids production was assessed using data 
available from DHI tests. Milk production in the first 
120 d of lactation was calculated using the test interval 
method (http://www.icar.org/documents/Rules%20
and%20regulations/Guidelines/Guidelines_2012.pdf).
Culling. The overall culling rates as well as the 
mastitis-specific culling rates were calculated in the 
first 120 and 305 d of lactation.
Data Collation and Statistical Analyses
Data were collated and initially analyzed using Ex-
cel and Access 2003 (Microsoft Corp., Redmond, WA) 
and Minitab 15.1 (Minitab Inc., State College, PA). 
Descriptive and graphical analyses were carried out 
to explore the data. When appropriate, groups were 
compared using ANOVA or, if data were not nor-
mally distributed, the Kruskal-Wallis test. Univariable 
analysis of treatment efficacy was performed using the 
chi-square test to investigate differences in proportions 
between groups; a layered Bonferroni correction was 
used to allow for multiple comparisons where appropri-
ate (Darlington, 1990).
When assessing the efficacy of the different regimens 
in the control of clinical mastitis and SCC and the ef-
fects on milk yield and culling, conventional multilevel 
(random effects) models (Goldstein, 1995) were speci-
fied so that correlations within the data were accounted 
for appropriately. General model specifications (for the 
binary outcomes) were as follows:
Yij ~ Bernoulli (probability = πij),
Logit (πij) = α + β1Xij + β2Xj + ujk,
 u Njk u~ , ,0
2σ( )  
where Y is the outcome under consideration; the sub-
scripts i and j denote the ith quarter and the jth cow, 
respectively; α is the regression intercept; Xij is the 
vector of covariates at quarter level and β1 the coeffi-
cients for covariates Xij; Xj is the vector of farm-year 
level covariates and β2 the coefficients for covariates 
Xj; ujk is the random effect to reflect residual variation 
between cows; and σu
2 = between-cow variance. Farm 
was included as a fixed effect in all models and a term 
for loge week of study was included to account for the 
underlying risk of mastitis over time. Equivalent mod-
els with normally distributed outcome variables were 
specified to separately investigate the effects of vacci-
nation routine on milk yield and milk solids.
Covariate assessment and selection was carried out 
using MLwiN with MQL (marginal quasi likelihood) or 
PQL (penalized quasi likelihood) for parameter estima-
tion (Rasbash et al., 2005). A significance probability 
was set at P < 0.05. Investigation of model fit was using 
standard methods as previously described (Goldstein, 
1995; Green et al., 2004).
Survival analysis was used to examine factors that 
influenced the risk of clinical mastitis or culling in the 
first 120 d of lactation. This was conducted using ML-
wiN following conventional methods, with the introduc-
tion of a lowest level of time (Collett, 1995).
RESULTS
In total, 3,130 cows from 7 farms were recruited to 
the study between September 2010 and January 2012; 
key characteristics of each of each of the farms and 
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the number of cows recruited from each are shown in 
Table 1. In total, 1,044, 1,046, and 1,040 cows were 
allocated to the unvaccinated, label, and rolling groups, 
respectively. Data from a total of 1,549 cows that calved 
(or would have calved in the case of the unvaccinated 
group) after 2 or more vaccinations were incorporated 
into the analyses; 576, 415, and 558 cows in the unvac-
cinated, label, and rolling groups, encompassing 642, 
416, and 638 lactations, respectively. As stipulated by 
the selection criteria above, cows in the label group 
had received 2 vaccinations by calving, whereas cows in 
the rolling group had received, on average, 4.26 (mini-
mum = 2, maximum = 7) vaccinations by calving. Key 
characteristics of cows used in the analysis of efficacy 
are outlined in Table 2 and did not vary significantly 
between the study groups.
Clinical and Subclinical Mastitis
In total, 4,237 cases of clinical mastitis occurred in 
all cows on the study farms during the study period, 
of which 779 occurred in the first 120 d of lactation 
in cows eligible for analysis of vaccine efficacy in early 
lactation. The etiology of clinical mastitis in cows on 
the study was complex (summarized in Table 3). Esch-
erichia coli was the most common cause of clinical mas-
titis, accounting for approximately one-fifth of cases, 
whereas all Enterobacteriaceae accounted for approxi-
Table 1. Key characteristics of the 7 study farms 
Characteristic
Study site
B C F H P R T
Herd size 190 568 218 231 286 205 581
Number of animals recruited 240 780 274 307 421 284 824
Bulk milk SCC1 (×103 cells/mL)
 1 mo before study 254 238 288 193 356 349 260
 2 mo before study 235 229 285 223 377 286 269
 3 mo before study 404 298 295 260 211 306 254
 At the end of study 217 468 283 201 288 526 310
Clinical mastitis incidence rate (cases/100 cows per year)
 In 12 mo before start of the study 36 111 67 114 40 149 41
 In 12 mo before the end of the study 82 38 55 101 86 147 48
305-d milk yield (L) 
 At the start of the study (cows and heifers) 8,843 9,280 9,918 9,012 8,917 8,758 10,654
 At the end of the study (cows and heifers) 8,454 10,352 9,401 9,547 8,753 8,725 10,542
Predominant housing2
 Dry cow–winter Y C, Y C, Y Y C, Y C, Y C, Y
 Lactating cow–winter C C C C C C C
 Dry cow–summer P P C, Y P P P Y
 Lactating cow–summer P C C P P P C
Predominant bedding
 Dry cows Straw Sand Sand Straw Straw Straw Straw
 Lactating cows Straw Straw Sand Sand Straw Straw Straw
Milking frequency (/d) 2× 3× 2× 2× 2× 2× 3×
1Calculated bulk milk SCC based on individual cow recordings.
2C = cubicles; Y = yards; P = pasture.
Table 2. Summary of the key data from cows included in the analysis of efficacy in early lactation1 
Item
Unvaccinated group Label group Rolling group
Mean Median Range Mean Median Range Mean Median Range
Parity 3.72 3 1–14 3.57 3 1–12 3.62 3 1–13
Last recorded yield before dry 
off (L)
18.3 17.7 1.5–51.6 18.0 17.6 2.8–43.9 18.2 17.4 1.2–50.6
ICSCC2 (×103 cells/mL)
 1 mo before dry off 371 174 12–8,062 301 121 6–4,440 384 181 10–8,486
 2 mo before dry off 269 121 11–6,771 244 122 4–5,333 277 143 8–5,267
 3 mo before dry off 255 108 9–6,602 227 107 8–6,883 259 115 6–9,203
1Cows in the unvaccinated group acted as negative controls and did not receive any vaccinations. Cows recruited to the label group were vac-
cinated at 45 d before the estimated date of calving (based on herd records), 35 d later, and 52 d postcalving. Cows recruited to the rolling 
group were vaccinated on the day of recruitment (d 0), 28 d later (d 28), 62 d thereafter (d 90), and then every 90 d until the end of the study. 
2ICSCC = individual cow SCC.
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mately one-quarter of cases, and gram-negative organ-
isms were implicated in approximately one-third of all 
clinical cases. Clinical cases caused by Staphylococcus 
aureus and the CNS were relatively rare, accounting for 
only 2.5 and 5.6% of cases, respectively.
The proportion of cows affected and rates of clinical 
mastitis in the first 120 d of lactation are summarized 
in Table 4. Survival curves for the overall occurrence of 
clinical mastitis in each group are illustrated in Figure 
1. Univariable and multivariable analysis failed to iden-
tify any significant differences in pathogen-specific or 
overall rates of clinical mastitis between the treatment 
groups. More specifically, when compared with unvacci-
nated cows, cows on the label and rolling regimens were 
no less likely to develop clinical mastitis [label regi-
men: odds ratio (OR) 0.91, 95% CI: 0.72–1.15; rolling 
regimen: OR 0.93, 95% CI: 0.76–1.14], coliform mastitis 
(label regimen: OR 1.22, 95% CI: 0.84–1.78; rolling 
regimen: OR 1.09, 95% CI: 0.77–1.53), staphylococcal 
mastitis (label regimen: OR 0.79, 95% CI: 0.54–1.16; 
rolling regimen: OR 0.88, 95% CI: 0.63–1.22), or clinical 
mastitis caused by a coliform or staphylococcal organ-
ism (label regimen: OR 1.04, 95% CI: 0.76–1.43; rolling 
regimen: OR 0.95, 95%CI: 0.71–1.26).
Somatic cell scores did not vary significantly (P > 
0.05) between the treatment groups at any of the test-
days during the first 120 d of lactation (see Table 5). 
The proportion of cows affected by subclinical mastitis 
and the rate of apparent new subclinical infection, as 
defined by an individual cow SCC >200,000 cells/mL 
Table 3. Summary of the etiology of clinical cases included in the analysis of efficacy in early lactation1 
Item
Unvaccinated Label group Rolling group Overall
n % n % n % n %
Number of cows 576 415 558 1,549
Number of lactations 642 416 638 1,696
Escherichia coli 58 19.86 42 21.54 60 20.55 160 20.54
Streptococcus uberis 61 20.89 33 16.92 61 20.89 155 19.90
Staphylococcus aureus 7 2.40 5 2.56 7 2.40 19 2.44
Enterococcus spp. 4 1.37 6 3.08 8 2.74 18 2.31
Streptococcus dysgalactiae 9 3.08   7 2.40 16 2.05
Yeast spp. 3 1.03 5 2.56 6 2.05 14 1.80
Bacillus spp. 6 2.05 2 1.03 3 1.03 11 1.41
Trueperella pyogenes 5 1.71   6 2.05 11 1.41
Enterobacter spp. 3 1.03 1 0.51 2 0.68 6 0.77
Klebsiella spp. 2 0.68 1 0.51 2 0.68 5 0.64
Serratia spp.   3 1.54 2 0.68 5 0.64
Lactococcus spp. 1 0.34   3 1.03 4 0.51
Pseudomonas spp. 1 0.34 2 1.03 1 0.34 4 0.51
Proteus spp.   2 1.03 1 0.34 3 0.39
Aerococcus spp. 2 0.68     2 0.26
Acinetobacter spp. 1 0.34   1 0.34 2 0.26
Aspergillus spp. 1 0.34 1 0.51   2 0.26
Micrococcus spp. 1 0.34   1 0.34 2 0.26
Streptococcus spp. 1 0.34   2 0.68 2 0.26
Prototheca spp.   2 1.03   2 0.26
Candida spp.   1 0.51   1 0.13
Citrobacter spp.   1 0.51   1 0.13
Gemella spp.   1 0.51   1 0.13
Pasteurella spp.   1 0.51   1 0.13
Staphylococcus spp.   1 0.51   1 0.13
Unspeciated gram-negative     1 0.34 1 0.13
All Enterobacteriaceae 63 21.58 50 25.64 67 22.95 180 23.11
Mixed etiology 35 11.99 33 16.92 31 10.62 99 12.71
Mixed with gram-negative involvement 29 9.93 20 10.26 23 7.88 72 9.24
Coagulase-negative Staphylococcus spp. 17 5.82 8 4.10 19 6.51 44 5.65
Corynebacterium spp. 6 2.05 6 3.08 13 4.45 25 3.21
Mixed minor pathogens 3 1.03 4 2.05 2 0.68 9 1.16
Contaminated 13 4.45 11 5.64 21 7.19 45 5.78
No growth 26 8.90 15 7.69 22 7.53 29 3.72
No sample 26 8.90 8 4.10 10 3.42 43 5.52
Total 292  195  292  779  
Cases/100 cow-lactations 45.5  46.9  45.8  45.9  
1Cows in the unvaccinated group acted as negative controls and did not receive any vaccinations. Cows recruited to the label group were at 45 
d before the estimated date of calving (based on herd records), 35 d later, and 52 d postcalving. Cows recruited to the rolling group were vac-
cinated on the day of recruitment (d 0), 28 d later (d 28), 62 d thereafter (d 90), and then every 90 d until the end of the study. 
1712 BRADLEY ET AL.
Journal of Dairy Science Vol. 98 No. 3, 2015
at any of the DHI tests in the first 120 d of lactation, 
were not significantly different between the treatment 
groups.
Mastitis Severity and Culling
The effect of vaccination on clinical mastitis severity 
was assessed using all cases of clinical mastitis occur-
ring in the first 120 d lactation; severity grades were 
available for 770 cases. The number and proportion 
of clinical mastitis cases falling into each of the sever-
ity classifications are outlined in Table 6. Univariable 
analysis failed to demonstrate any significant difference 
in the proportion of cases falling into each severity clas-
sifications between treatment groups.
Multivariable analysis taking into account confound-
ing factors such as mastitis etiology, parity, and farm 
effects demonstrated a significant effect of vaccination, 
with cows on the label regimen being at significantly 
decreased odds of developing clinical mastitis manifest-
ing with more than just changes in the milk aspect 
(OR 0.58, 95% CI: 0.35–0.98). Details of the model are 
outlined in Table 7. Similarly, multivariable analysis 
demonstrated that an increasing number of vaccina-
tions decreased the severity of clinical signs, as outlined 
in Table 8, with each additional vaccination resulting 
in a cow being at decreased odds of developing clinical 
mastitis manifesting with more than just changes in 
the milk aspect (OR 0.87, 95% CI: 0.77–0.98). These 
models also demonstrated that cases of clinical coliform 
mastitis were more likely to be severe than cases caused 
by other pathogens and that large variation in severity 
existed between study farms.
The overall culling rates and the mastitis-specific 
culling rates were calculated for the first 120 and 305 
d of lactation, the findings of which are summarized in 
Table 9. Rates of culling were low, with only 14 (2.2%), 
6 (1.4%), and 15 (2.4%) of cows being culled in the un-
vaccinated, label, and rolling groups, respectively. No 
significant effects of vaccination were detected. How-
ever, there were proportionally fewer mastitis culls in 
the label-vaccinated group, and the only toxic and fatal 
cases of mastitis occurred in the unvaccinated group. 
Because farmers tend to be reluctant to cull cows in 
early lactation, our analysis of the effect of vaccination 
on culling was extended to encompass the first 305 d 
of lactation. This revealed a significant difference in 
the total number of cows culled between the treatment 
Table 4. Summary of the proportion of cows affected and rates of clinical mastitis, caused by pathogens incorporated in the vaccine, in the first 
120 d of lactation in the 3 treatment groups1 
Item
Unvaccinated group Label group Rolling group
Proportion 
of cows 
affected
Cases/100 
cow-lactations
Proportion 
of cows 
affected
Cases/100 
cow-lactations
Proportion 
of cows 
affected
Cases/100 
cow-lactations
Number of cows 576 415 558
Number of lactations 642 416 638
All cases 0.334 45.5 0.321 46.9 0.332 45.8
Escherichia coli 0.098 9.5 0.116 7.9 0.113 9.6
Coliforms 0.112 9.8 0.128 12.0 0.124 10.5
Staphylococcus aureus 0.013 1.1 0.020 1.2 0.017 1.1
Coagulase-negative Staphylococcus spp. 0.069 2.7 0.064 1.9 0.062 3.0
All Staphylococcus spp. 0.078 3.7 0.081 3.4 0.071 4.1
All coliforms and Staphylococcus spp. 0.167 13.6 0.175 15.4 0.167 14.6
1Cows in the unvaccinated group acted as negative controls and did not receive any vaccinations. Cows recruited to the label group were vac-
cinated at 45 d before the estimated date of calving (based on herd records), 35 d later, and 52 d postcalving. Cows recruited to the rolling 
group were vaccinated on the day of recruitment (d 0), 28 d later (d 28), 62 d thereafter (d 90), and then every 90 d until the end of the study. 
Figure 1. Illustration of the survival of cows to the first case of 
clinical mastitis in each of the treatment groups. Cows in the unvac-
cinated group acted as negative controls and did not receive any vac-
cinations. Cows recruited to the label group were vaccinated at 45 
d before the estimated date of calving (based on herd records), 35 d 
later, and 52 d postcalving. Cows recruited to the rolling group were 
vaccinated on the day of recruitment (d 0), 28 d later (d 28), 62 d 
thereafter (d 90), and then every 90 d until the end of the study. No 
significant differences were identified between the treatment groups.
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groups, with 26.2, 18.3, and 24.2% of cows being culled 
in the unvaccinated, label, and rolling groups, respec-
tively. Significantly fewer cows were culled from the 
label group than from either the unvaccinated (76/340 
vs. 168/474: P = 0.02) or the rolling groups (76/340 
vs. 155/483: P = 0.04), although the unvaccinated and 
rolling groups did not differ (168/474 vs. 155/483: P = 
0.88). Exploration of the data to identify cows in which 
at least part of the reason for culling was mastitis re-
vealed that 4.2, 3.1, and 3.8% of cows were culled in the 
unvaccinated, label, and rolling groups, respectively, in 
the first 305 d of lactation. Although proportionally, 
the fewest cows were culled for reasons related to mas-
titis in the label-vaccinated group, the differences were 
not significant. Multivariable analysis was performed 
to take into account potentially confounding factors for 
mastitis-related culling, but failed to identify a signifi-
cant effect of vaccination.
Milk Production
The effect of vaccination on milk production was 
assessed using data available from DHI tests. The 
mean and median individual test-day and total 120-d 
milk production data of cows in each of the treatment 
groups are summarized in Table 10 and illustrated in 
Figure 2. The yields at individual recordings and the 
calculated cumulative 120-d yields varied significantly 
between treatment groups (P < 0.05). Similarly, total 
milk protein produced varied significantly between the 
treatment groups (P < 0.05), whereas total milk but-
terfat did not; overall milk solids production also varied 
significantly between treatment groups (P < 0.01)
Multivariable analysis demonstrated that, on aver-
age, cows in the label group produced a significantly 
higher volume of milk (231 L; 95% CI: 104.1–357.4) 
than unvaccinated cows in the first 120 d of lactation. 
However, when a second model was specified that took 
into account the occurrence of clinical mastitis and 
elevated SCC at herd test-days, the impact of vaccina-
tion in the label group decreased to approximately 204 
L, as summarized in Table 11. As might be expected, 
we observed significant variation between farms but 
not between parities. Spring-calving cows yielded be-
tween 218 and 516 L more milk than cows calving in 
other seasons. Culling was associated with the largest 
reduction in yield (1,892 L; 95% CI: 1,654–1,892). Each 
1-L increase in yield at the last recording of the previ-
ous lactation was associated with a 17.42-L (95% CI: 
11.01–23.83) increase in yield in the first 120 d of the 
subsequent lactation. A case of clinical mastitis was 
associated with a reduction in yield of 23.3 L, although 
this effect was not significant (95% CI: −129.8–83.3); 
in contrast, each unit log increase in individual cow Ta
b
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SCC at the first and second herd test-days resulted in 
reductions in yield of 101.8 L (95% CI: 64.9–138.7) and 
64.6 L (95% CI: 27.9–101.3), respectively.
A similar model was specified to explore the effect of 
vaccination on milk solids production, the findings of 
which are summarized in Table 12. This demonstrated 
that cows in the label group produced 12.36 kg (95% CI: 
3.12–21.60) more milk solids in the first 120 d of lacta-
tion compared with unvaccinated herdmates. Again, we 
observed significant variation between farms and sea-
sons, but, interestingly, not between parities. Culling 
was associated with the largest reduction in production 
of milk solids (137.0 kg; 95% CI: 113.5–160.4). A case 
of clinical mastitis was associated with a reduction in 
milk solids production of 9.07 kg (95% CI: 0.85–17.29). 
Each unit log increase in individual cow SCC at the 
first and second herd test-days resulted in reductions in 
milk solids production of 6.87 kg (95% CI: 4.03–9.71) 
and 4.40 kg (95% CI: 1.58–7.22), respectively.
DISCUSSION
The ultimate target of developing and implementing 
the use of a vaccine in the control of a disease complex 
such as mastitis should be displacement of disease; that 
is, an absolute reduction in the overall incidence of 
disease, irrespective of cause. However, a possible and 
plausible outcome is one of substitution rather than 
displacement; that is, the vaccine effectively controls 
one opportunistic pathogen such as E. coli, but a pro-
portion of the inherently susceptible cows that are now 
protected from one opportunistic pathogen become 
Table 6. Summary of the severity of clinical signs of mastitis in cases occurring in the first 120 d of lactation1 
Grade
Unvaccinated group Label group Rolling group Overall
n % n % n % n %
Milk signs only 137 47.24 106 54.92 156 54.36 399 51.82
Milk and udder signs 123 42.41 70 36.27 116 40.42 309 40.13
Systemic signs 22 7.59 12 6.22 12 4.18 46 5.97
Toxic signs 8 2.76 5 2.59 3 1.05 16 2.08
Total cases 290  193  287  770  
1Cows in the unvaccinated group acted as negative controls and did not receive any vaccinations. Cows recruited to the label group were vac-
cinated at 45 d before the estimated date of calving (based on herd records), 35 d later, and 52 d postcalving. Cows recruited to the rolling 
group were vaccinated on the day of recruitment (d 0), 28 d later (d 28), 62 d thereafter (d 90), and then every 90 d until the end of the study. 
Table 7. Summary of the significant terms in the multilevel logistic regression model1,2  
Term Coefficient SE
Odds  
ratio
95% CI
Lower Upper
Label regimen −0.54 0.26 0.58 0.35 0.98
Rolling regimen −0.38 0.23 0.69 0.43 1.08
Referent: unvaccinated      
Parity 2 0.92 0.43 2.50 1.06 5.89
Parity 3 0.57 0.41 1.77 0.78 4.04
Parity 4 1.04 0.43 2.82 1.20 6.65
Parity ≥5 0.25 0.39 1.29 0.59 2.81
Referent: Parity 1      
Farm C 4.07 0.61 58.62 17.24 199.34
Farm F 2.95 0.61 19.14 5.62 65.24
Farm H 2.38 0.59 10.85 3.33 35.37
Farm P 2.09 0.62 8.05 2.35 27.61
Farm R 2.95 0.60 19.03 5.70 63.56
Farm T −1.77 0.91 0.17 0.03 1.05
Referent: Farm B      
Coliform clinical case 0.63 0.19 1.88 1.28 2.77
Referent: Noncoliform case      
1Cows in the unvaccinated group acted as negative controls and did not receive any vaccinations. Cows re-
cruited to the label group were vaccinated at 45 d before the estimated date of calving (based on herd records), 
35 d later, and 52 d postcalving. Cows recruited to the rolling group were vaccinated on the day of recruitment 
(d 0), 28 d later (d 28), 62 d thereafter (d 90), and then every 90 d until the end of the study.
2Outcome 1 = a case of severe mastitis in the first 120 d of lactation, 0 = no case of severe mastitis in the 
first 120 d of lactation. Severe mastitis was defined by more than just changes in the milk (e.g., swollen udder, 
sick cow).
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infected with another (e.g., Streptococcus uberis). Al-
though not definitively substantiated, the failure of this 
study, in common with many other vaccination studies 
(Hogan et al., 1992; Wilson et al., 2007a; Gurjar et al., 
2013), to detect a reduction in the overall rate of clini-
cal mastitis may have been due, in part, to this effect.
Another reason why this and other field studies 
may have failed to detect any effect of vaccination on 
the incidence of clinical mastitis may have been that 
vaccine efficacy in the field is due to a combination 
of direct and indirect effects. Studies such as this can 
estimate the direct effect of the vaccine (i.e., efficacy 
of the use of a vaccine in an individual in which it is 
used based on a given level of exposure) but cannot 
easily account for the indirect vaccine effect (i.e., the 
effect that vaccination of individuals in a population 
has on the level of exposure by virtue of reduction in 
the amount of pathogen present in the population; Hal-
loran and Struchiner, 1991). However, given that the 
primary aim of this study was to look at the efficacy 
of the vaccine with respect to coliform mastitis control, 
and that the prevalence of contagious mastitis patho-
gens in the herds selected was low, we might reasonably 
expect any indirect effects of the vaccine to be small. 
This is because of the general assumptions that the pri-
mary mode of transmission of coliform mastitis is from 
the environment to the cow, that infected cows do not 
make a significant contribution to the level of challenge, 
and that “contagious” spread of coliforms from cow to 
cow, although reported (Bradley and Green, 2001), is 
thought to be relatively rare.
Another recent study (Schukken et al., 2014) has 
investigated the field efficacy of the polyvalent vac-
cine described in this paper. In contrast to the cur-
rent study, that study focused on the efficacy of the 
staphylococcal component of the vaccine. Their design 
Table 8. Summary of the significant terms in the multilevel logistic regression model describing the effect of 
an increasing number of vaccinations on mastitis severity1 
Term Coefficient SE
Odds  
ratio
95% CI
Lower Upper
Number of vaccinations −0.15 0.06 0.87 0.77 0.98
Parity 2 0.72 0.36 2.06 1.00 4.22
Parity 3 −0.04 0.35 0.96 0.48 1.93
Parity 4 0.08 0.37 1.08 0.51 2.29
Parity ≥5 0.12 0.34 1.13 0.57 2.23
Referent: Parity 1      
Farm C 4.51 0.79 90.56 18.73 437.90
Farm F 3.41 0.80 30.36 6.10 150.96
Farm H 2.99 0.78 19.83 4.15 94.73
Farm P 2.40 0.81 11.00 2.19 55.26
Farm R 3.09 0.79 21.89 4.50 106.48
Farm T −0.60 0.91 0.55 0.09 3.40
Referent: Farm B      
Coliform mastitis case 0.66 0.23 1.93 1.22 3.04
Staphylococcal mastitis case 0.13 0.26 1.13 0.68 1.90
No growth mastitis case −0.31 0.46 0.73 0.30 1.83
Referent: other mastitis case      
1Outcome 1 = a case of severe mastitis in the first 120 d of lactation, 0 = no case of severe mastitis in the first 
120 d of lactation.
Table 9. Summary of culling during lactation in the 3 treatment groups1 
Item
Unvaccinated group Label group Rolling group
n % n % n %
Number of lactations 642 416 638
All culls in first 120 d in lactation 66 10.3 35 8.4 54 8.5
Mastitis culls in first 120 d in lactation 14 2.2 6 1.4 15 2.4
All culls in first 305 d in lactation 168 26.2b 76 18.3a 155 24.2b
Mastitis culls in first 305 d in lactation 27 4.2 13 3.1 24 3.9
a,bColumns within rows are significantly different (P < 0.05).
1Cows in the unvaccinated group acted as negative controls and did not receive any vaccinations. Cows re-
cruited to the label group were vaccinated at 45 d before the estimated date of calving (based on herd records), 
35 d later, and 52 d postcalving. Cows recruited to the rolling group were vaccinated on the day of recruitment 
(d 0), 28 d later (d 28), 62 d thereafter (d 90), and then every 90 d until the end of the study. 
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took into account both direct and indirect vaccine ef-
fects and involved a longitudinal study of subclinical 
and clinical infections, reporting a reduction in the 
reproduction ratio for Staph. aureus and CNS of 45 and 
35%, respectively. Similar findings were unlikely in our 
study because the focus was on clinical mastitis and en-
vironmental rather than contagious mastitis pathogens; 
furthermore, the incidence of staphylococcal mastitis 
was much lower in the herds used in this study that in 
the 2 herds selected by Schukken et al. (2014).
The etiology of clinical mastitis in this study was 
very complex, with more than 40 genera identified. 
This level of identification was only possible because of 
the use of MALDI-TOF MS for bacterial identification. 
Although this relatively new technique has not been 
extensively used in mastitis diagnostics, some small-
scale studies have demonstrated its utility in this field 
(Barreiro et al., 2010). In addition, extensive in-house 
validation, funded by the UK Technology Strategy 
Board, has been undertaken by the laboratory used 
in this study (QMMS Ltd.) and the instrument has 
the IVD-CE mark with a Declaration of Conformity 
in accordance with the European Commission (1998). 
Use of this new technique will not have introduced any 
bias in the study because it was used across all treat-
ment groups. Adoption of high-throughput proteomic 
techniques such as this are likely to offer an opportu-
nity to refine and enrich our understanding of mastitis 
etiology, which is still constrained by the limitations 
of existing techniques, as illustrated by a recent pub-
lication reviewing the identification of environmental 
streptococci (Werner et al., 2014). Moreover, the use 
of MALDI-TOF MS holds promise as a technique for 
rapid, cost-effective sub-species strain typing (Rizzardi 
et al., 2013).
A concern with field studies such as this is the po-
tential for bias. In this study, the risk of bias was mini-
mized by the use of randomization tables in allocation 
of cows to treatment groups, and because no form of 
identification was used that allowed easy identification 
of cows based on their treatment group. Moreover, al-
though bias could have been introduced in the subjec-
tive identification of clinical mastitis, other outcomes 
used in the study such as yield and SCC could not be 
influenced by study personnel. Additionally, laboratory 
personnel undertaking somatic cell counting and bacte-
riology were completely blinded to product administra-
tion.
One observation which cause for concern was that, 
in the analysis, the label group only contained 416 
animals, compared to 638 and 642 in the rolling and 
control groups, respectively. This difference arose from 
the fact that cows were only included in the analysis if 
they had received (or would have received) 2 vaccina-Ta
b
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tions by the time of calving. Despite good cow records, 
achieving this objective was more challenging in the 
label group than in the rolling group because the label 
protocol for the vaccine called for precise scheduling of 
vaccinations around the period of highest perceived risk 
(i.e., calving and early lactation). This is an important 
observation because it reflects an important clinical 
consideration in implementing a mastitis vaccination 
program—whether the farmer can manage or achieve 
the required vaccination protocol.
In common with others (Hogan et al., 1992; Wilson 
et al., 2007a), this study demonstrated that vaccina-
tion significantly reduces the severity of clinical disease 
and that increasing the number of vaccinations is as-
sociated with decreasing severity of clinical symptoms. 
As we might expect, coliform mastitis was associated 
with more severe disease. Of interest is the very large 
variation in the odds of severe disease between farms. 
Several factors are important in determining the sever-
ity of coliform mastitis, including the levels of vitamin 
E and selenium (Smith and Hogan, 1993) as well as 
negative energy balance (Suriyasathaporn et al., 1999). 
In practice in the field, it is often assumed that the 
highest-yielding cows will be those most at risk of nega-
tive energy balance and thereby severe disease; in this 
study, the farm with the highest milk volume (farm T) 
had the lowest odds of a severe case of mastitis, and 
the herd with the highest odds of severe disease (farm 
C) was the herd with, by far, the highest milk solids 
production. This effect on severity may also explain, 
in part, why some studies have reported an apparent 
reduction in clinical mastitis following vaccination and 
others have not; it may be that the reduction in the 
severity of clinical signs on some farms is sufficient to 
reduce signs below the threshold of detection for un-
skilled and poorly motivated staff.
Other studies have reported a significant effect of 
vaccination on culling associated with mastitis (Wilson 
et al., 2007a), which has been used as the economic 
justification for the use of J5 vaccines (DeGraves and 
Fetrow, 1991). In this study, although we observed a 
significant reduction in the rate of culling in the label 
group compared with the rolling and unvaccinated 
groups in the first 305 d of lactation, this was not 
evident in early lactation during the period of claimed 
vaccine efficacy. Furthermore, when culling related to 
mastitis was considered, no significant effects could 
be identified, which may have been due, in part, to 
the relatively low proportion of the study herds being 
culled for mastitis reasons (fertility tended to be the 
most common reason for culling).
Perhaps the most intriguing and financially impor-
tant finding of this study is the effect that vaccination 
had on milk production in early lactation. Earlier stud-
ies have demonstrated that vaccination results in less 
loss in yield in cows experiencing mastitis (Wilson et 
Figure 2. An illustration of the effect of vaccination on milk yield recorded on each of the first 4 DHI test-days (1st to 4th) occurring in the 
first 120 d of lactation. Cows in the unvaccinated group acted as negative controls and did not receive any vaccinations. Cows recruited to the 
label group were vaccinated at 45 d before the estimated date of calving (based on herd records), 35 d later, and 52 d postcalving. Cows recruited 
to the rolling group were vaccinated on the day of recruitment (d 0), 28 d later (d 28), 62 d thereafter (d 90), and then every 90 d until the end 
of the study. a,bDifferent letters within test-day groups are significantly different (P < 0.05). Error bars denote SE.
1718 BRADLEY ET AL.
Journal of Dairy Science Vol. 98 No. 3, 2015
al., 2007b, 2008), but this is the first study to have 
demonstrated such an effect in the vaccinated popula-
tion as a whole. Initial models demonstrated that the 
label-vaccinated group produced almost 2 L more milk 
per day in the first 120 d of lactation, whereas cows 
in the rolling vaccination group produced almost 1 L 
more per day when compared with the unvaccinated 
group, although the effect was not significant. What 
is intriguing in this study is that this effect (albeit di-
luted) persisted even when one accounts for the effect 
of a cow being affected by clinical mastitis or having a 
higher SCC in early lactation. Interestingly, the effect 
of clinical mastitis was relatively small (only a 23-L 
reduction in yield) when the effect of increased SCC 
was accounted for. Although an increase in milk volume 
is of interest, producers’ payments in many markets 
are linked to the production of milk solids rather than 
milk volume. Analysis of milk solids production dem-
onstrated a similar effect to that seen with yield, with 
label-vaccinated cows producing around 12 kg more 
milk solids in the first 120 d of lactation. The reason 
for this increase in yield in the vaccinated cows is not 
immediately apparent, though it would seem fair to as-
sume it was not all due to direct effects of the vaccine 
on the mammary gland, given that these have been 
controlled for in the models by inclusion of terms for 
clinical mastitis and SCC. Further scrutiny of the data 
relating to solids production suggests that the effect of 
vaccination was relatively greater on production of pro-
tein than on butterfat; therefore, the butterfat:protein 
ratio would be lower in vaccinated cows, which could 
suggest less severe negative energy balance in those 
cows (Duffield et al., 1997). In this study, all 3 groups 
of cows were managed together throughout the study 
period, so it was not possible to determine whether 
the vaccinated cows produced more milk as a result 
of higher feed intake or through more efficient feed 
conversion; this would be an interesting area of further 
research that might help us better understand this ap-
parently important effect of mastitis vaccination.
We did not attempt to model any economic ben-
efits of vaccination in this study, in part because of 
the complexity of any production effects. However, we 
can assume that vaccination is likely to prove economi-
cally beneficial in higher-yielding herds experiencing a 
high proportion of severe mastitis, because even if the 
increase in milk production is associated with a com-
parable increase in feed intake, the return is still likely 
to be significant. In February 2014, the margin over 
all feed costs reported by DairyCo in the United King-
dom (http://www.dairyco.org.uk/market-information/ 
farming-data/promar-milkminder-dairy-costings/ 
promar-milkminder-dairy-costings-national/#. 
U0-BWHJOVaQ) was 17.88 Pence per liter, suggesting 
Table 11. Summary of the multilevel model exploring the effect of vaccination on cumulative milk yield in 
the first 120 d of lactation1 
Term Coefficient SE
95% CI
Lower Upper
Label regimen 204.23 59.50 85.23 323.24
Rolling regimen 102.37 52.99 −3.61 208.36
Referent: unvaccinated     
Farm C 874.18 95.63 682.92 1,065.44
Farm F 286.73 110.92 64.88 508.57
Farm H 297.45 103.99 89.48 505.42
Farm P 129.87 121.17 −112.47 372.20
Farm R −131.47 113.20 −357.88 94.94
Farm T 747.77 101.47 544.83 950.70
Referent: Farm B     
Parity 2 −302.41 894.80 −2,092.01 1,487.19
Parity 3 −112.09 895.69 −1,903.48 1,679.30
Parity 4 15.34 895.69 −1,776.05 1,806.73
Parity ≥5 54.44 894.68 −1,734.92 1,843.81
Referent: Parity 1     
Summer −342.85 76.91 −496.66 −189.04
Autumn −516.66 72.88 −662.43 −370.90
Winter −218.58 69.15 −356.87 −80.28
Referent: Spring     
LnSCC2 at 1st recording −101.80 18.44 −138.68 −64.91
LnSCC at 2nd recording −64.58 18.34 −101.27 −27.89
Animals that were culled −1,892.05 118.76 −2,129.57 −1,654.52
Animals that developed clinical mastitis −23.26 53.26 −129.79 83.27
Last recorded yield of the previous lactation (L) 17.42 3.21 11.01 23.83
1The outcome is a continuous variable cumulative milk yield (L) in the first 120 d of lactation.
2LnSCC = natural log of the SCC.
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that the marginal additional yield produced by label-
vaccinated cows in this study would have been worth 
£41.12, offering a return on investment (assuming a 
vaccine cost of £5.34 per dose) of approximately 2.57:1 
with respect to milk yield alone.
CONCLUSIONS
The utility of a commercially available, polyvalent 
mastitis vaccine was investigated under UK field condi-
tions. Use of the vaccine was not associated with a de-
crease in the incidence of clinical or subclinical mastitis 
in the first 120 DIM. However, vaccinated cows were 
significantly less likely to experience severe clinical 
mastitis and produced significantly more milk and milk 
solids than unvaccinated herdmates.
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